Elizabeth Clutterbuck

Author

Also Known As

Clutterbuck, EA, Clutterbuck, Elizabeth, Clutterbuck, Elizabeth Ann, Daniel O’Connor, E Clutterbuck, E. Clutterbuck, Elizabeth A. Clutterbuck, Elizabeth A Clutterbuck, Elizabeth A. Clutterbuck, Elizabeth Ann Clutterbuck

135

Publications

22.2K

Citations

H-Index

Concepts

All Affiliations

University of Oxford Oxford BioMedica (United Kingdom)Jenner Institute Centre for Human Genetics Oxford University Hospitals NHS Trust

About

Elizabeth Clutterbuck is an author at University of Oxford specializing in immunology, vaccination, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	6.4K
2	Allergy	6	6	1.6K
3	Health Sciences	1	1	32
4	Public Health	1	1	35
5	Cell Biology	1	1	22

Elizabeth Clutterbuck

Publications

19K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, The Lancet VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	2.6K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, Cell	2021	1.1K
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai, Cell Viral DiagnosticsVaccine SeraImmunologyViral PathogenesisUnited Kingdom	2021	744
Antibody evasion by the P.1 strain of SARS-CoV-2 Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, Cell	2021	655
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, The Lancet	2021	649
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Nature Medicine VaccinationVaccine DevelopmentAllergyImmunologyImmunodominance	2020	633
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial Xinxue Liu, R. H. Shaw, Arabella Stuart, The Lancet VaccinationVaccine SafetyVaccine DevelopmentAdenoviral VectoredImmunology	2021	539
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, reponame:Expeditio Repositorio Institucional UJTL VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	536

Page 1